SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 244 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $209 | -16.7% | 7,570 | 0.0% | 0.02% | -20.0% |
| Q2 2023 | $251 | -8.4% | 7,570 | 0.0% | 0.02% | -9.1% |
| Q1 2023 | $274 | +1.5% | 7,570 | 0.0% | 0.02% | -4.3% |
| Q4 2022 | $270 | -99.9% | 7,570 | 0.0% | 0.02% | -4.2% |
| Q3 2022 | $256,000 | -5.9% | 7,570 | -10.2% | 0.02% | +14.3% |
| Q1 2022 | $272,000 | -15.0% | 8,430 | -18.8% | 0.02% | -19.2% |
| Q2 2021 | $320,000 | +17.6% | 10,380 | 0.0% | 0.03% | +4.0% |
| Q1 2021 | $272,000 | +4.2% | 10,380 | 0.0% | 0.02% | 0.0% |
| Q4 2020 | $261,000 | +20.8% | 10,380 | 0.0% | 0.02% | +4.2% |
| Q3 2020 | $216,000 | -13.6% | 10,380 | 0.0% | 0.02% | -17.2% |
| Q2 2020 | $250,000 | +33.7% | 10,380 | 0.0% | 0.03% | +11.5% |
| Q1 2020 | $187,000 | -19.4% | 10,380 | +47.9% | 0.03% | -31.6% |
| Q2 2019 | $232,000 | -5.7% | 7,020 | 0.0% | 0.04% | -11.6% |
| Q1 2019 | $246,000 | +20.0% | 7,020 | +105.3% | 0.04% | 0.0% |
| Q2 2018 | $205,000 | – | 3,420 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
| ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
| ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
| S&T BANK/PA | 215,578 | $5,943 | 1.15% |
| Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
| Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
| Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
| Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
| Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |